Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling

Journal of Immunology

Volumn 179, Issue 11, 2007, Pages 7295-7304

  Elpek, Kutlu G ^a   Yolcu, Esma S ^a   Franke, Deanna D H ^a   Lacelle, Chantale ^a   Schabowsky, Rich Henry ^a   Shirwan, Haval ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD137 LIGAND; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 4; STREPTAVIDIN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; CD137 ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, MOUSE; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; BAGG ALBINO MOUSE; C57BL 6 MOUSE; CD4+ CD25+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SELECTION; CELL SUSPENSION; CONTROLLED STUDY; EX VIVO STUDY; HOMEOSTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR BINDING; REGULATORY MECHANISM; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSPLANTATION; UPREGULATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; DISEASE MODEL; DRUG EFFECT; GENE EXPRESSION PROFILING; GENETICS; GRAFT REJECTION; IMMUNOLOGY; PANCREAS ISLET; PANCREAS ISLET TRANSPLANTATION; SIGNAL TRANSDUCTION;

4-1BB LIGAND; ANIMALS; ANTIGENS, CD137; CELL PROLIFERATION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION PROFILING; GRAFT REJECTION; INTERLEUKIN-2; ISLETS OF LANGERHANS; ISLETS OF LANGERHANS TRANSPLANTATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STREPTAVIDIN; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 38849108168     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.11.7295     Document Type: Article

References (61)

1. + regulatory T cells induced by an agonist self-peptide. Nat. Immunol. 2: 301-306.
2. + regulatory T cells. Curr. Opin. Immunol. 17: 131-136.
3. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155: 1151-1164.
4. + regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6: 345-352.
5. Bennett, C. L., J. Christie, F. Ramsdell, M. E. Brunkow, P. J. Ferguson, L. Whitesell, T. E. Kelly, F. T. Saulsbury, P. F. Chance, and H. D. Ochs. 2001. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27: 20-21.
6. Brunkow, M. E., E. W. Jeffery, K. A. Hjerrild, B. Paeper, L. B. Clark, S. A. Yasayko, J. E. Wilkinson, D. Galas, S. F. Ziegler, and F. Ramsdell. 2001. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27: 68-73.
7. Suzuki, H., T. M. Kundig, C. Furlonger, A. Wakeham, E. Timms, T. Matsuyama, R. Schmits, J. J. Simard, P. S. Ohashi, H. Griesser, et al. 1995. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor β. Science 268: 1472-1476.
8. + Treg cells. Transplantation 79: 1492-1497.
9. Wood, K. J., and S. Sakaguchi. 2003. Regulatory T cells in transplantation tolerance. Nat. Rev. Immunol. 3: 199-210.
10. + regulatory T cells. J. Exp. Med. 202: 885-891.
11. + suppressor T cells regulate pathogen induced inflammation and disease. FEMS Immunol. Med. Microbiol. 44: 121-127.
12. Terabe, M., and J. A. Berzofsky. 2004. Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol. 16: 157-162.
13. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188: 287-296.
14. Grossman, W. J., J. W. Verbsky, W. Barchet, M. Colonna, J. P. Atkinson, and T. J. Ley. 2004. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 21: 589-601.
15. + T cells through TGF-β-TGF-β receptor interactions in type 1 diabetes. Proc. Natl. Acad. Sci. USA 100: 10878-10883.
16. Asseman, C., S. Mauze, M. W. Leach, R. L. Coffman, and F. Powrie. 1999. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J. Exp. Med. 190: 995-1004.
17. + regulatory T cells. Proc. Natl. Acad. Sci. USA 103: 5460-5465.
18. + T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J. Immunol. 176: 1582-1587.
19. Mellor, A. L., and D. H. Munn. 2004. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4: 762-774.
20. + regulatory T cells in human thymus. Nature 436: 1181-1185.
21. + regulatory T cells. Novartis Found. Symp. 252: 55-63.
22. Malek, T. R. 2003. The main function of IL-2 is to promote the development of T regulatory cells. J. Leukocyte Biol. 74: 961-965.
23. + regulatory T cells. Trends Immunol. 25: 374-380.
24. + regulatory T cells. Blood 105: 4743-4748.
25. + regulatory T cells suppress effector T cell proliferation. Clin. Immunol. 115: 3-9.
26. + T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 104: 453-461.
27. Tang, Q., K. J. Henriksen, M. Bi, E. B. Finger, G. Szot, J. Ye, E. L. Masteller, H. McDevitt, M. Bonyhadi, and J. A. Bluestone. 2004. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J. Exp. Med. 199: 1455-1465.
28. Marshall, E. 2006. Drug trials. Violent reaction to monoclonal antibody therapy remains a mystery. Science 311: 1688-1689.
29. + T cells. J. Leukocyte Biol. 75: 785-791.
30. + immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 16: 311-323.
31. Watts, T. H. 2005. TNF/TNFR family members in costimulation of T cell responses. Annu. Rev. Immunol. 23: 23-68.
32. Vinay, D. S., and B. S. Kwon. 1998. Role of 4-1BB in immune responses. Semin. Immunol. 10: 481-489.
33. Cheuk, A. T., G. J. Mufti, and B. A. Guinn. 2004. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Ther. 11: 215-226.
34. Tan, J. T., J. K. Whitmire, K. Murali-Krishna, R. Ahmed, J. D. Altman, R. S. Mittler, A. Sette, T. C. Pearson, and C. P. Larsen. 2000. 4-1BB costimulation is required for protective anti-viral immunity after peptide vaccination. J. Immunol. 164: 2320-2325.
35. Foell, J. L., B. I. Diez-Mendiondo, O. H. Diez, U. Holzer, P. Ruck, A. S. Bapat, M. K. Hoffmann, R. S. Mittler, and G. E. Dannecker. 2004. Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance. Immunology 113: 89-98.
36. Polte, T., J. Foell, C. Werner, H. G. Hoymann, A. Braun, S. Burdach, R. S. Mittler, and G. Hansen. 2006. CD137-mediated immunotherapy for allergic asthma. J. Clin. Invest. 116: 1025-1036.
37. Baccam, M., and G. A. Bishop. 1999. Membrane-bound CD154, but not CD40-specific antibody, mediates NF-κB-independent IL-6 production in B cells. Eur. J. Immunol. 29: 3855-3866.
38. Kovacs, B., R. V. Parry, Z. Ma, E. Fan, D. K. Shivers, B. A. Freiberg, A. K. Thomas, R. Rutherford, C. A. Rumbley, J. L. Riley, and T. H. Finkel. 2005. Ligation of CD28 by its natural ligand CD86 in the absence of TCR stimulation induces lipid raft polarization in human CD4 T cells. J. Immunol. 175: 7848-7854.
39. Martinet, O., C. M. Divino, Y. Zang, Y. Gan, J. Mandeli, S. Thung, P. Y. Pan, and S. H. Chen. 2002. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer. Gene Ther. 9: 786-792.
40. Rabu, C., A. Quéméner, Y. Jacques, K. Echasserieau, P. Vusio, and F. Lang. 2005. Production of recombinant human trimeric CD137L(4-1BBL): crosslinking is essential to its T cell co-stimulation activity. J. Biol. Chem. 280: 41472-41481.
41. Saoulli, K., S. Y. Lee, J. L. Cannons, W. C. Yeh, A. Santana, M. D. Goldstein, N. Bangia, M. A. DeBenedette, T. W. Mak, Y. Choi, and T. H. Watts. 1998. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J. Exp. Med. 187: 1849-1862.
42. Singh, N. P., E. S. Yolcu, D. D. Taylor, C. Gercel-Taylor, D. S. Metzinger, S. K. Dreisbach, and H. Shirwan. 2003. A novel approach to cancer immunotherapy: tumor cells decorated with CD80 generate effective antitumor immunity. Cancer Res. 63: 4067-4073.
43. Yolcu, E. S., N. Askenasy, N. P. Singh, S. E. Cherradi, and H. Shirwan. 2002. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 17: 795-808.
44. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses. J. Exp. Med. 186: 47-55.
45. Croft, M. 2003. Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 3: 609-620.
46. Viola, A., S. Schroeder, Y. Sakakibara, and A. Lanzavecchia. 1999. T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 283: 680-682.
47. Carbonnelle, D., F. Ebstein, C. Rabu, J. Y. Petit, M. Gregoire, and F. Lang. 2005. A new carboxamide compound exerts immuno-suppressive activity by inhibiting dendritic cell maturation. Eur. J. Immunol. 35: 546-556.
48. Kilinc, M. O., L. Mukundan, E. S. Yolcu, N. P. Singh, J. Suttles, and H. Shirwan. 2006. Generation of a multimeric form of CD40L with potent immunostimulatory activity using streptavidin as a chaperon. Exp. Mol. Pathol. 80: 252-261.
49. Goodwin, R. G., W. S. Din, T. Davis-Smith, D. M. Anderson, S. D. Gimpel, T. A. Sato, C. R. Maliszewski, C. I. Brannan, N. G. Copeland, N. A. Jenkins, et al. 1993. Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor. Eur. J. Immunol. 23: 2631-2641.
50. Weber, P. C., D. H. Ohlendorf, J. J. Wendoloski, and F. R. Salemme. 1989. Structural origins of high-affinity biotin binding to streptavidin. Science 243: 85-88.
51. + regulatory T cells. J. Immunol. 173: 2428-2434.
52. + T cells for IL-2 and exploit it for the induction of IL-10 production. Int. Immunol. 17: 279-288.
53. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182: 18-32.
54. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192: 303-310.
55. high regulatory T cells. Blood 104: 895-903.
56. + regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3: 135-142.
57. + T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 105: 2845-2851.
58. Kim, J. O., H. W. Kim, K. M. Baek, and C. Y. Kang. 2003. NF-κB and AP-1 regulate activation-dependent CD137 (4-1BB) expression in T cells. FEBS Lett. 541: 163-170.
59. Verdeil, G., D. Puthier, C. Nguyen, A. M. Schmitt-Verhulst, and N. Auphan-Anezin. 2006. STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors. J. Immunol. 176: 4834-4842.
60. + T cell suppressor function. J. Immunol. 172: 6519-6523.
61. + T-cell effector differentiation by TGF-β1 and 4-1BB costimulation. Blood 105: 274-281.